Myeloid cell interactions in atherosclerosis
Myeloid cell interactions in atherosclerosis
批准号:
9311933
负责人:
Klaus F. Ley
金额:
$45.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-01 至 2021-04-30
关键词:
AddressAntigen PresentationAortaApolipoprotein EAreaArterial Fatty StreakArteriesAtherosclerosisBehaviorBiological ModelsBromodeoxyuridineCell CommunicationCell ShapeCellsCessation of lifeCharacteristicsColorDancingDataDendritesEndothelial CellsEndotheliumExternal carotid artery structureFundingGene ExpressionGene Expression ProfileGenesGeneticHot SpotITGAM geneImageIn SituInflammationInjectableIntegrin alpha4beta1IntegrinsLabelLeukocytesLigandsMeasuresMethodsMicroscopyMinimally modified Low Density LipoproteinModernizationMolecularMolecular ProfilingMonoclonal AntibodiesMovementMusMutationMyeloid CellsMyocardial InfarctionNaturePatternPeripheral arterial diseasePhenotypePrimary PreventionProliferatingResearchSecondary PreventionSpottingsStrokeSurfaceTechnologyTestingTimeWorkbasecadherin 5cell typechemokinechemokine receptordeep sequencingdifferential expressionexperimental studygenome-wideimage processingimaging systemin vivointravital microscopylive cell imagingmacrophagemicroscopic imagingmigrationmonocytemovieoxidized low density lipoproteinprogramstooltranscriptometranscriptome sequencinguptake
中文摘要
描述
尽管在一级和二级预防方面取得了巨大进展,但
动脉粥样硬化(心脏病、中风和外周动脉疾病)仍然是死亡人数最多的原因。
全世界。在这里,我们建议检验三个假设。这项工作已经成为可能通过生命中的
我们在当前资金周期中开发的活细胞触发成像系统(ILTIS)。假设1是非-
经典的单核细胞使用LFA-1(αLβ2整合素)和~40%的VLA-4(α4β1整合素)来巡视内皮
上面有动脉粥样硬化斑块。我们有初步证据表明至少有两个巡逻单核细胞亚群
在动脉粥样硬化的动脉中。为了测试巡逻的分子机制,我们将阻断整合素及其配体,
使用单抗检测趋化因子和趋化因子受体。假设2是血液单核细胞获得
通过管腔内皮细胞进入动脉粥样硬化斑块。测试单核细胞如何进入动脉粥样硬化
损伤,我们已经使小鼠的黄色(YFP)内皮细胞进入APOE-/-动脉粥样硬化-
俯卧背景。将这些小鼠与单核细胞亚群被荧光标记的小鼠相结合
(Cx3cr1GFP/+用于非经典单核细胞,Ccr2RFP/+用于经典单核细胞)将显示
体内单核细胞转化为动脉粥样硬化斑块。假设3是四个新发现的斑块巨噬细胞
子集(由ILTIS提供)具有不同的功能。初步的RNA-Seq数据显示,它们的基因表达谱
差异很大。我们将测试这些功能:BrdU和Ki67的增殖;oxLDL和最低限度的修饰
(Mm)低密度脂蛋白摄取;胞吐作用;迁移和抗原提呈。当建议的工作完成后,我们
将第一次知道单核细胞如何巡视动脉粥样硬化的动脉,如何进入动脉粥样硬化
损伤以及它们在那里做了什么。我们将确定四个新发现的单核细胞的关键功能,并
动脉粥样硬化斑块中巨噬细胞亚群。
英文摘要
Description
Although tremendous progress has been made in primary and secondary prevention, the complications of
atherosclerosis (heart attacks, strokes and peripheral artery disease) still account for the most deaths
worldwide. Here, we propose to test three hypotheses. This work has become possible through the intravital
live cell triggered imaging system (ILTIS) we developed in the current funding cycle. Hypothesis 1 is that non-
classical monocytes use LFA-1 (αLβ2 integrin) and ~40% also VLA-4 (α4β1 integrin) to patrol the endothelium
overlying atherosclerotic plaque. We have preliminary evidence for at least two subsets of patrolling monocytes
in atherosclerotic arteries. To test the molecular mechanism of patrolling, we will block integrins, their ligands,
chemokines and chemokine receptors using monoclonal antibodies. Hypothesis 2 is that blood monocytes gain
access to atherosclerotic plaque through the luminal endothelium. To test how monocytes enter atherosclerotic
lesions, we have made mice with yellow (YFP) endothelium that are crossed into the Apoe-/- atherosclerosis-
prone background. Combining these mice with mice in which monocyte subsets are fluorescently labeled
(Cx3cr1GFP/+ for non-classical, Ccr2RFP/+ for classical monocytes) will show transendothelial migration of
monocytes into atherosclerotic plaque in vivo. Hypothesis 3 is that four newly discovered plaque macrophage
subsets (by ILTIS) have different functions. Preliminary RNA-Seq data show that their gene expression profiles
vary significantly. We will test these functions: proliferation by BrdU and Ki67; oxLDL and minimally modified
(mm)LDL uptake; efferocytosis; migration and antigen presentation. When the proposed work is complete, we
will know, for the first time, how monocytes patrol atherosclerotic arteries, how they enter atherosclerotic
lesions and what they do there. We will identify key functions of the four newly discovered monocyte and
macrophage subsets in atherosclerotic plaque.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of kindlin-3-dependent integrin activation
-
批准号:10676897
-
项目类别:
-
资助金额:$54.92万
-
财政年份:2020
-
负责人:Klaus F. Ley
-
依托单位:
Mechanism of kindlin-3-dependent integrin activation
-
批准号:10229369
-
项目类别:
-
资助金额:$54.93万
-
财政年份:2020
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10112954
-
项目类别:
-
资助金额:$90.72万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10369710
-
项目类别:
-
资助金额:$58.9万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:9895858
-
项目类别:
-
资助金额:$90.7万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10623034
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10565907
-
项目类别:
-
资助金额:$76.97万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Core E: Cell sorting, CyTOF and RNA-Seq
-
批准号:10188604
-
项目类别:
-
资助金额:$54.45万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Core B: Single Cell Protein and RNA Sequencing Core
-
批准号:10334092
-
项目类别:
-
资助金额:$5.35万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Super-resolution confocal microscope
-
批准号:9274885
-
项目类别:
-
资助金额:$56.63万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
ApoB-specific CD4 T cells in mouse and human atherosclerosis
-
批准号:10188608
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosis
-
批准号:10334097
-
项目类别:
-
资助金额:$4.3万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Vaccination with MHC-II restricted ApoB100 peptides to prevent atherosclerosis
-
批准号:8819012
-
项目类别:
-
资助金额:$45.55万
-
财政年份:2014
-
负责人:Klaus F. Ley
-
依托单位:
Vaccination with MHC-II restricted ApoB100 peptides to prevent atherosclerosis
-
批准号:8966694
-
项目类别:
-
资助金额:$43.63万
-
财政年份:2014
-
负责人:Klaus F. Ley
-
依托单位:
VASCULATA 2013: Vascular Immunology
-
批准号:8597858
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2013
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8675936
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8346057
-
项目类别:
-
资助金额:$56.61万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8499418
-
项目类别:
-
资助金额:$43.3万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:9065736
-
项目类别:
-
资助金额:$43.35万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Cell Phenotyping Core
-
批准号:8703257
-
项目类别:
-
资助金额:$10.93万
-
财政年份:2008
-
负责人:Klaus F. Ley
-
依托单位:
海外基金